Remsima/Inflectra (infliximab biosimilars) are launched in the UK- Napp Pharma + Hospira
Napp Pharma has launched Remsima (infliximab biosimilar) in the United Kingdom at the same time as Hospira launched Inflectra (infliximab biosimilar) in the same market, both versions being licensed from and manufactured by Celltrion. The indication covers Crohns Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriasis at a price 30% less than originator drug Remicade. The companies face a biosimilar educational challenge as a survey within the National Health disclosed little understanding of these new biosimilar drugs.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins